Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Ezekowitz

Showing results (71-80 of 187) with videos related to

Pageof 19
Sort By:
The Lancet. Neurology|November 10, 2010
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trialHans-Christoph Diener, Stuart J Connolly, Michael D Ezekowitz, et al.
Circulation|September 25, 2003
Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty: a potential role of tissue factorEmmanuelle Jeanpierre, Thierry Le Tourneau, Isabelle Six, et al.
Circulation. Arrhythmia and Electrophysiology|October 22, 2009
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS studyTaya V Glotzer, Emile G Daoud, D George Wyse, et al.
Heart (British Cardiac Society)|May 6, 2014
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudyZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
Stroke|January 2, 2010
Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic eventsPaul D Ziegler, Taya V Glotzer, Emile G Daoud, et al.
American Heart Journal|August 2, 2017
Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trialZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|January 28, 2020
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT TrialPaulus Kirchhof, Michael D Ezekowitz, Yanish Purmah, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|December 30, 2011
A randomized trial of budiodarone in paroxysmal atrial fibrillationMichael D Ezekowitz, Rangadham Nagarakanti, Andrzej Lubinski, et al.
Circulation|September 12, 2014
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin"Ammar Majeed, Hun-Gyu Hwang, Stuart J Connolly, et al.
Journal of the American College of Cardiology|October 1, 2013
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)Paul A Reilly, Thorsten Lehr, Sebastian Haertter, et al.
Pageof 19

Showing results (71-80 of 187) with videos related to

Sort By:
Pageof 19
The Lancet. Neurology|November 10, 2010
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trialHans-Christoph Diener, Stuart J Connolly, Michael D Ezekowitz, et al.
Circulation|September 25, 2003
Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty: a potential role of tissue factorEmmanuelle Jeanpierre, Thierry Le Tourneau, Isabelle Six, et al.
Circulation. Arrhythmia and Electrophysiology|October 22, 2009
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS studyTaya V Glotzer, Emile G Daoud, D George Wyse, et al.
Heart (British Cardiac Society)|May 6, 2014
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudyZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
Stroke|January 2, 2010
Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic eventsPaul D Ziegler, Taya V Glotzer, Emile G Daoud, et al.
American Heart Journal|August 2, 2017
Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trialZiad Hijazi, Jonas Oldgren, Ulrika Andersson, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|January 28, 2020
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT TrialPaulus Kirchhof, Michael D Ezekowitz, Yanish Purmah, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|December 30, 2011
A randomized trial of budiodarone in paroxysmal atrial fibrillationMichael D Ezekowitz, Rangadham Nagarakanti, Andrzej Lubinski, et al.
Circulation|September 12, 2014
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin"Ammar Majeed, Hun-Gyu Hwang, Stuart J Connolly, et al.
Journal of the American College of Cardiology|October 1, 2013
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)Paul A Reilly, Thorsten Lehr, Sebastian Haertter, et al.
Pageof 19